Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis: The aim of this study was to evaluate the impact on metabolic control of periodic use of a 5-day fasting-mimicking diet (FMD) programme as an adjunct to usual care in people with type 2 diabetes under regular primary care surveillance. Methods: In this randomised, controlled, assessor-blinded trial, people with type 2 diabetes using metformin as the only glucose-lowering drug and/or diet for glycaemic control were randomised to receive 5-day cycles of an FMD monthly as an adjunct to regular care by their general practitioner or to receive regular care only. The primary outcomes were changes in glucose-lowering medication (as reflected by the medication effect score) and HbA 1c levels after 12 months. Moreover, changes in use of glucose-lowering medication and/or HbA 1c levels in individual participants were combined to yield a clinically relevant outcome measure (‘glycaemic management’), which was categorised as improved, stable or deteriorated after 1 year of follow-up. Several secondary outcome measures were also examined, including changes in body weight. Results: One hundred individuals with type 2 diabetes, age 18–75 years, BMI ≥27 kg/m 2, were randomised to the FMD group (n=51) or the control group (n=49). Eight FMD participants and ten control participants were lost to follow-up. Intention-to-treat analyses, using linear mixed models, revealed adjusted estimated treatment effects for the medication effect score (−0.3; 95% CI −0.4, −0.2; p<0.001), HbA 1c (−3.2 mmol/mol; 95% CI −6.2, −0.2 and −0.3%; 95% CI −0.6, −0.0; p=0.04) and body weight (−3.6 kg; 95% CI −5.2, −2.1; p<0.001) at 12 months. Glycaemic management improved in 53% of participants using FMD vs 8% of control participants, remained stable in 23% vs 33%, and deteriorated in 23% vs 59% (p<0.001). Conclusions/interpretation: Integration of a monthly FMD programme in regular primary care for people with type 2 diabetes who use metformin as the only glucose-lowering drug and/or diet for glycaemic control reduces the need for glucose-lowering medication, improves HbA 1c despite the reduction in medication use, and appears to be safe in routine clinical practice. Trial registration: ClinicalTrials.gov NCT03811587 Funding: The project was co-funded by Health~Holland, Top Sector Life Sciences & Health, the Dutch Diabetes Foundation and L-Nutra. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that short cycles of very-low-calorie intake, such as those used in FMDs, can lead to decreases in fat mass while preserving lean mass, improved physical performance, and glucoregulation”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [230]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They often use periodic, proprietary 5-day protocols using meal replacements which can be convenient, but potentially prohibitively expensive for patients”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [230]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“However, severely restricting energy intake for extended periods is burdensome for many people and reduces energy expenditure [11], making weight maintenance a challenge in the long term [12].”
BackgroundEffects of intermittent fasting on health, aging, and disease
de Cabo, R., & Mattson, M. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1905136 · Cited by 1,605 · cited 1×
“Fasting evokes evolutionarily conserved adaptive hormonal and cellular responses that enhance stress resistance, dampen inflammation and optimise metabolism [1].”
BackgroundLim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“Limiting dietary intake to approximately 3560 kJ/day (850 kcal/day) for 12–20 weeks, followed by structural support for weight loss maintenance, facilitates disease remission in people with type 2 diabetes [8–10].”
BackgroundLean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017 · cited 1×
“Limiting dietary intake to approximately 3560 kJ/day (850 kcal/day) for 12–20 weeks, followed by structural support for weight loss maintenance, facilitates disease remission in people with type 2 diabetes [8–10].”
BackgroundMaintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876
Brandhorst, S., Choi, I. Y., Wei, M., Cheng, C. W., Sedrakyan, S., Navarrete, G., Dubeau, L., Yap, L. P., Park, R., Vinciguerra, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.012 · Cited by 850
Self-citationCaloric restriction improves health and survival of rhesus monkeys
Mattison, J. A., Colman, R. J., Beasley, T. M., Allison, D. B., Kemnitz, J. W., Roth, G. S., Ingram, D. K., Weindruch, R., de Cabo, R., & Anderson, R. M. (2017) · Nature Communications · doi:10.1038/ncomms14063 · Cited by 838
Anson, R. M., Guo, Z., de Cabo, R., Iyun, T., Rios, M., Hagepanos, A., Ingram, D. K., Lane, M. A., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1035720100 · Cited by 731
Health benefits of gastric bypass surgery after 6 years
Adams, T. D., Davidson, L. E., Litwin, S. E., Kolotkin, R. L., LaMonte, M. J., Pendleton, R. C., Strong, M. B., Vinik, R., Wanner, N. A., Hopkins, P. N., et al. (2012) · JAMA · doi:10.1001/2012.jama.11164 · Cited by 674
Utzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572 · cited 1×
“%) higher at the end of the study compared with baseline with no change in glucose-lowering medication disposition index (reflecting endogenous insulin secretion) [25–27].”
Wei, M., Brandhorst, S., Shelehchi, M., Mirzaei, H., Cheng, C. W., Budniak, J., Groshen, S., Mack, W. J., Guen, E., Di Biase, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8700 · Cited by 553 · cited 2×
“In healthy (non-diabetic) humans, three 5-day cycles of FMD monthly were shown to reduce fat mass, BP, triglyceride levels and fasting glucose, particularly in people with high levels of these risk factors at baseline [17].”
BackgroundMethodSelf-citationDifferent ways to estimate treatment effects in randomised controlled trials
J, T., L, B., T, H., J, R., M, W., & M, H. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.03.008 · Cited by 532 · cited 1×
“The models were adjusted for the baseline value of the outcome and for randomisation stratifiers (sex and weight >100 kg) [29].”
MethodFasting and cancer: molecular mechanisms and clinical application
Nencioni, A., Caffa, I., Cortellino, S., & Longo, V. D. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0061-0 · Cited by 518
Self-citationAccurate Assessment of β-Cell Function
Bergman, R. N., Ader, M., Huecking, K., & Van Citters, G. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s212 · Cited by 516
Di Francesco, A., Di Germanio, C., Bernier, M., & de Cabo, R. (2018) · Science · doi:10.1126/science.aau2095 · Cited by 497
Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes
Cheng, C.-W., Villani, V., Buono, R., Wei, M., Kumar, S., Yilmaz, O. H., Cohen, P., Sneddon, J. B., Perin, L., & Longo, V. D. (2017) · Cell · doi:10.1016/j.cell.2017.01.040 · Cited by 331
Self-citationFallacies of last observation carried forward analyses
Lachin, J. M. (2016) · Clinical Trials · doi:10.1177/1740774515602688 · Cited by 328
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219
Effects of intermittent fasting on glucose and lipid metabolism
Antoni, R., Johnston, K. L., Collins, A. L., & Robertson, M. D. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665116002986 · Cited by 198
Liu, H., Javaheri, A., Godar, R. J., Murphy, J., Ma, X., Rohatgi, N., Mahadevan, J., Hyrc, K., Saftig, P., Marshall, C., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1368596 · Cited by 189
Protein Quantity and Source, Fasting-Mimicking Diets, and Longevity
Brandhorst, S., & Longo, V. D. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz079 · Cited by 99
Self-citationFasting-mimicking diet prevents high-fat diet effect on cardiometabolic risk and lifespan
Mishra, A. K., Mirzaei, H., Guidi, N., Vinciguerra, M., Mouton, A., Linardić, M., Rappa, F., Barone, R., Navarrete, G., Wei, M., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00469-6 · Cited by 84
Self-citationCox, D. J., Banton, T., Moncrief, M., Conaway, M., Diamond, A., & McCall, A. L. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa118 · Cited by 82
Sulaj, A., Kopf, S., von Rauchhaupt, E., Kliemank, E., Brune, M., Κender, Ζ., Bartl, H., Cortizo, F. G., Klepac, K., Han, Z., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac197 · Cited by 66
Self-citationAlexopoulos, A.-S., Yancy, W. S., Edelman, D., Coffman, C. J., Jeffreys, A. S., Maciejewski, M. L., Voils, C. I., Sagalla, N., Barton Bradley, A., Dar, M., et al. (2021) · Chronic Illness · doi:10.1177/1742395319884096 · Cited by 44
van den Burg, E. L., van Peet, P. G., Schoonakker, M. P., van de Haar, D. E., Numans, M. E., & Pijl, H. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad015 · Cited by 33
Self-citationTang, F. X., & Lin, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6615295 · Cited by 31
van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., Marle, M. E. V. D. A., van Dijk, K. W., Longo, V. D., Lamb, H. J., Numans, M. E., & Pijl, H. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00576-7 · Cited by 28
Self-citationCox, D. J., Oser, T., Moncrief, M., Conaway, M., & McCall, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002403 · Cited by 11
Cited by
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“They often use periodic, proprietary 5-day protocols using meal replacements which can be convenient, but potentially prohibitively expensive for patients [230].”
Metadata
- Authors
- van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H.
- Affiliations
- Leiden University Medical Center (NL)
- University of Southern California (US)
- ORCID
- Venue
- Diabetologia
- Published
- 2024-03-28
- Volume
- 67
- Issue
- 7
- Pages
- 1245-1259
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11153305
- OpenAlex
- W4393258687
- Cited by
- 25
- References
- 33
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Funders
- L-Nutra
- Diabetes Fonds
- Health~Holland
- Topics
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fasting-mimicking diet, type 2 diabetes, glycemic control, HbA1c, metformin, primary care, body weight, intermittent fasting, weight loss, metabolic control, cost-effectiveness, quality of life
- MeSH terms
- Glycemic Control, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Primary Health Care, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.